PARP1 and colitis: FK866, a small NAMPT inhibitor, reduces mucosal NAD+ and NAD+-dependent enzymes (including PARP1, SIRT6, and CD38), NF-κB pathway activation, and inflammatory cell infiltration, thereby improving DSS-induced colitis in mice and preventing inflammation-related tumors [18].